Arbutus Launches $230M Dutch Auction Tender Offer at $5.00–$5.75
ABUS sits 53% above its 52-week low of $3.44.
Summary
Arbutus Biopharma announced a modified Dutch auction tender offer to repurchase up to $230 million of its common shares at $5.00–$5.75 per share, expected to commence August 24, 2026.
Key Events · Financing and Capital Events · ABUS
-
Dutch Auction Tender Offer Announced
Arbutus plans to repurchase up to US$230 million of common shares through a modified Dutch auction tender offer at a price range of US$5.00 to US$5.75 per share.
-
Offer Timeline
The offer is expected to commence on or about August 24, 2026, and expire on or about September 29, 2026, subject to regulatory exemptive relief.
-
Funding Source
The repurchase will be funded entirely from cash on hand, which was bolstered by the $178.4 million Moderna settlement payment received in July 2026.
-
Premium to Market
The offer price range of $5.00–$5.75 is at or above the current stock price of $5.27, indicating a willingness to pay a premium to return capital.
Analysis · ABUS · Life Sciences
Arbutus is moving forward with its previously announced $230 million share repurchase via a modified Dutch auction tender offer. The price range of $5.00 to $5.75 brackets the current stock price of $5.27, indicating the company is willing to pay a premium to return capital to shareholders. This is a significant return of capital, representing roughly 24% of the company's market cap, and signals management's confidence in the company's cash position following the Moderna settlement.
At the time of this filing, ABUS was trading at $5.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $943.7M. The 52-week trading range was $3.44 to $5.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.